Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Poland
  4. Warsaw Stock Exchange
  5. Ryvu Therapeutics S.A.
  6. Summary
    RVU   PLSELVT00013

RYVU THERAPEUTICS S.A.

(RVU)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Warsaw Stock Exchange
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
59.2 61.4 61.4 60.7 59.7 Last
11558 7506 15379 4238 2362 Volume
-1.17% +3.72% 0.00% -1.14% -1.65% Change
Estimated financial data (e)
Sales 2021 28,4 M 7,23 M 7,23 M
Net income 2021 -66,2 M -16,9 M -16,9 M
Net cash position 2021 108 M 27,5 M 27,5 M
P/E ratio 2021 -
Yield 2021 -
Sales 2022 29,1 M 7,41 M 7,41 M
Net income 2022 -68,2 M -17,4 M -17,4 M
Net cash position 2022 57,0 M 14,5 M 14,5 M
P/E ratio 2022 -
Yield 2022 -
Capitalization 1 079 M 275 M 275 M
EV / Sales 2021 34,2x
EV / Sales 2022 35,1x
Nbr of Employees -
Free-Float 67,8%
More Financials
Company
Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as... 
More about the company
Ratings of Ryvu Therapeutics S.A.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about RYVU THERAPEUTICS S.A.
09/08Ryvu Therapeutics S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2..
CI
08/25Ryvu Therapeutics S.A. Announces First Patient Dosed in Phase I/II Study of RVU120 in P..
CI
07/14Ryvu Therapeutics S.A. Announces FDA Lifts Partial Clinical Hold on Phase IB Clinical T..
CI
06/11Ryvu Therapeutics Presents Positive Phase I Data for Rvu120 of Phase I/Ii Data for Sel2..
CI
06/01Ryvu Therapeutics Announces Results SEL24 Clinical Data from DIAMOND-01 Trial to be Pre..
CI
05/28Ryvu Therapeutics S.A. Got Full Approval to Conduct Phase I/Ii Study of Rvu120 in Patie..
CI
05/12Ryvu Therapeutics S.A. to Present Clinical and Translational Data from RVU120 at the Vi..
CI
05/12Ryvu Therapeutics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2..
CI
04/26Ryvu Therapeutics Appoints Vatnak Vat-Ho as Chief Business Officer
CI
04/08Ryvu Therapeutics S.A. Announces Partial Clinical Hold of Phase Ib Clinical Trial of RV..
CI
03/16Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 20..
CI
03/09Ryvu Signs a Deal for Phase I Clinical Trials for its RVU120 Drug
CI
02/25EDISON INVESTMENT RESEARCH LIMITED : Ryvu Therapeutics (RVU): Rebalancing R&D pipeline tow..
DJ
2020Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter Ended September 3..
CI
2020Selvita Provides Earnings Guidance for the Third Quarter of 2020
CI
More news
News in other languages on RYVU THERAPEUTICS S.A.

- No features available -

More news
Chart RYVU THERAPEUTICS S.A.
Duration : Period :
Ryvu Therapeutics S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RYVU THERAPEUTICS S.A.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus SELL
Number of Analysts 1
Last Close Price 59,70 PLN
Average target price 53,00 PLN
Spread / Average Target -11,2%
Managers and Directors
Pawel Przewiezlikowski Chief Executive Officer
Piotr Romanowski Chairman-Supervisory Board
Krzysztof Brzozka Chief Scientific Officer
Setareh van Driel Shamsili Chief Medical Officer
Kamil Sebastian Sitarz Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
RYVU THERAPEUTICS S.A.21.34%278
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353